Answer
Patients older than 65 years receiving Vanflyta need close monitoring for severe infections during induction because fatal infections occurred more frequently with quizartinib in this age group than in younger patients, especially early in treatment.
Sources for this answer
- Vanflyta 17.7 mg film-coated tabletDaiichi Sankyo UK Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 4Document updated
Sources checked